{"id":"buserelin","rwe":[{"pmid":"41538921","year":"2026","title":"Reproductive efficiency of Bos indicus cows under different estradiol-free ovulation synchronization protocols.","finding":"","journal":"Theriogenology","studyType":"Clinical Study"},{"pmid":"41489804","year":"2026","title":"Effect on insulin clearance of different pharmacological treatments in women with polycystic ovary syndrome: a hypothesis-generative study.","finding":"","journal":"Journal of endocrinological investigation","studyType":"Clinical Study"},{"pmid":"41473569","year":"2025","title":"Optimal timing for triggering oocyte maturation during in vitro fertilization cycles varies between gonadotropin-releasing hormone agonist and human chorionic gonadotropin use.","finding":"","journal":"F&S reports","studyType":"Clinical Study"},{"pmid":"41397337","year":"2026","title":"Association of buserelin acetate with estradiol benzoate in early resynchronization of Bos taurus beef heifers improved conception rates.","finding":"","journal":"Theriogenology","studyType":"Clinical Study"},{"pmid":"41343948","year":"2026","title":"Estradiol esters are dispensable in progesterone-based TAI protocols for Bos taurus suckling beef cows.","finding":"","journal":"Animal reproduction science","studyType":"Clinical Study"}],"tags":[{"label":"buserelin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Gonadotropin-releasing hormone receptor","category":"target"},{"label":"GNRHR","category":"gene"},{"label":"LHCGR","category":"gene"},{"label":"L02AE01","category":"atc"},{"label":"Active","category":"status"},{"label":"Induction of final follicular maturation","category":"indication"},{"label":"Prevention of premature ovulation","category":"indication"},{"label":"Sanofi K.K.","category":"company"},{"label":"Fertility Agents, Female","category":"pharmacology"},{"label":"Reproductive Control Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":108.354,"date":"","count":17,"signal":"Ovarian hyperstimulation syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 17 times (LLR=108)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Sanofi K.K.","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BUSERELIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:10:21.978998+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Buserelin","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:10:28.884866+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:10:27.409877+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BUSERELIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:10:27.799690+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2106198/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:10:28.522077+00:00"}},"allNames":"receptal","offLabel":[],"synonyms":["buserelin","etilamide","receptal","buserelin acetate","suprecur"],"timeline":[{"date":"1984-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"},{"date":"2022-02-25","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Sanofi K.K.)"}],"brandName":"Receptal","ecosystem":[{"indication":"Induction of final follicular maturation","otherDrugs":[],"globalPrevalence":null},{"indication":"Prevention of premature ovulation","otherDrugs":[{"name":"cetrorelix","slug":"cetrorelix","company":"Emd Serono Inc"},{"name":"nafarelin","slug":"nafarelin","company":"Gd Searle Llc"}],"globalPrevalence":null}],"mechanism":{"target":"Gonadotropin-releasing hormone receptor","targets":[{"gene":"GNRHR","source":"DrugCentral","target":"Gonadotropin-releasing hormone receptor","protein":"Gonadotropin-releasing hormone receptor"},{"gene":"LHCGR","source":"DrugCentral","target":"Lutropin-choriogonadotropic hormone receptor","protein":"Lutropin-choriogonadotropic hormone receptor"}],"modality":"Peptide","drugClass":"buserelin","explanation":"","oneSentence":"","technicalDetail":"Receptal acts as a competitive agonist at the gonadotropin-releasing hormone receptor, stimulating the release of gonadotropin-releasing hormone and subsequently leading to the downregulation of gonadotropin secretion, which in turn induces final follicular maturation and prevents premature ovulation."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Buserelin","title":"Buserelin","extract":"Buserelin, sold under the brand name Suprefact among others, is a medication which is used primarily in the treatment of prostate cancer and endometriosis. It is also used for other indications such as the treatment of premenopausal breast cancer, uterine fibroids, and early puberty, in assisted reproduction for female infertility, and as a part of transgender hormone therapy. In addition, buserelin is used in veterinary medicine. The medication is typically used as a nasal spray three times per day, but is also available for use as a solution or implant for injection into fat.","wiki_history":"==History==\nBuserelin was first described in 1976 and was introduced for medical use in 1984. Intranasal buserelin was the first GnRH agonist demonstrated to achieve medical castration in humans. This was initially observed via a marked decrease in circulating testosterone levels in a single patient in 1980.","wiki_society_and_culture":"==Society and culture==\n\n===Generic names===\nBuserelin is the generic name of the drug and its  and , while buserelin acetate is its , , and , buséréline is its , and buserelina is its . While under development by Hoechst AG, buserelin was also known as HOE-766. It is not available in the United States or Australia."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/436","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BUSERELIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BUSERELIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Buserelin","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T09:05:57.908906","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:10:30.354891+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"leuprorelin","drugSlug":"leuprorelin","fdaApproval":"1985-04-09","relationship":"same-class"},{"drugName":"goserelin","drugSlug":"goserelin","fdaApproval":"1989-12-29","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"triptorelin","drugSlug":"triptorelin","fdaApproval":"2000-06-15","patentExpiry":"Jun 30, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"histrelin","drugSlug":"histrelin","fdaApproval":"1991-12-24","patentExpiry":"Jun 16, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"bicalutamide","drugSlug":"bicalutamide","fdaApproval":"1995-10-04","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"buserelin","indications":{"approved":[{"name":"Induction of final follicular maturation","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Prevention of premature ovulation","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"leuprorelin","brandName":"leuprorelin","genericName":"leuprorelin","approvalYear":"1985","relationship":"same-class"},{"drugId":"goserelin","brandName":"goserelin","genericName":"goserelin","approvalYear":"1989","relationship":"same-class"},{"drugId":"triptorelin","brandName":"triptorelin","genericName":"triptorelin","approvalYear":"2000","relationship":"same-class"},{"drugId":"histrelin","brandName":"histrelin","genericName":"histrelin","approvalYear":"1991","relationship":"same-class"},{"drugId":"bicalutamide","brandName":"bicalutamide","genericName":"bicalutamide","approvalYear":"1995","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00936390","phase":"PHASE3","title":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-09","conditions":["Prostate Cancer"],"enrollment":1538,"completionDate":"2025-09-04"},{"nctId":"NCT01546987","phase":"PHASE3","title":"Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2012-05","conditions":["Prostate Cancer"],"enrollment":239,"completionDate":"2025-09-04"},{"nctId":"NCT05050084","phase":"PHASE3","title":"Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-12-06","conditions":["Prostate Adenocarcinoma"],"enrollment":2050,"completionDate":"2026-11-11"},{"nctId":"NCT04513717","phase":"PHASE3","title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2021-01-21","conditions":["Prostate Adenocarcinoma","Stage III Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8"],"enrollment":2753,"completionDate":"2033-12-31"},{"nctId":"NCT01492972","phase":"PHASE3","title":"Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer","status":"RECRUITING","sponsor":"Proton Collaborative Group","startDate":"2012-01","conditions":["Prostate Cancer"],"enrollment":192,"completionDate":""},{"nctId":"NCT07076719","phase":"","title":"Cell-free DNA Analysis of Spent Embryo Culture Media as a Non-invasive Approach for Preimplantation Genetic Diagnosis","status":"COMPLETED","sponsor":"Sohag University","startDate":"2023-10-01","conditions":["to Evaluate the Feasibility and Accuracy of Using cfDNA Analysis of Spent Embryo Culture Media as a Non-invasive Approach for PGD"],"enrollment":20,"completionDate":"2024-08-28"},{"nctId":"NCT00567580","phase":"PHASE3","title":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radiation Therapy Oncology Group","startDate":"2008-02","conditions":["Prostate Cancer"],"enrollment":1792,"completionDate":""},{"nctId":"NCT05149131","phase":"","title":"A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-01-17","conditions":["Metastatic Castration-sensitive Prostate Cancer"],"enrollment":960,"completionDate":"2022-08-16"},{"nctId":"NCT06199960","phase":"PHASE3","title":"Dual Ovarian Stimulation (Duostim) and Shanghai Protocols in Poor Ovarian Responders","status":"COMPLETED","sponsor":"Royan Institute","startDate":"2019-08-02","conditions":["Assisted Reproductive Techniques"],"enrollment":116,"completionDate":"2023-11-20"},{"nctId":"NCT05567731","phase":"NA","title":"Effect of GnRH Agonist Treatment Protocols on Ovarian Reserve","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-10-15","conditions":["Intracytoplasmic Sperm Injection","GnRH Agonist","Infertility","Ovarian Reserve"],"enrollment":30,"completionDate":"2023-12-01"},{"nctId":"NCT00651326","phase":"PHASE3","title":"Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer","status":"TERMINATED","sponsor":"NCIC Clinical Trials Group","startDate":"2008-06-02","conditions":["Prostate Cancer"],"enrollment":48,"completionDate":"2011-01-18"},{"nctId":"NCT00054106","phase":"PHASE1","title":"Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2002-12-10","conditions":["Prostate Cancer"],"enrollment":25,"completionDate":"2008-09-22"},{"nctId":"NCT05638529","phase":"PHASE4","title":"Dual Trigger\" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome","status":"UNKNOWN","sponsor":"Mount Sinai Hospital, Canada","startDate":"2019-05-01","conditions":["Ovarian Hyperstimulation Syndrome","Infertility, Female"],"enrollment":80,"completionDate":"2023-12-31"},{"nctId":"NCT05801705","phase":"","title":"Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-06-01","conditions":["Hormone-receptor-positive Breast Cancer","Premenopausal Breast Cancer","Breast Cancer Patients at Intermediate to High Risk","Ovarian Function Suppression Combined With Aromatase Inhibitor or Tamoxifen or Torimefen"],"enrollment":700,"completionDate":"2023-12-30"},{"nctId":"NCT04168892","phase":"","title":"Anti-Müllerian Hormone (AMH) Measured With Fully Automated Assay Versus AFC in the Prediction of Ovarian Response","status":"COMPLETED","sponsor":"Andros Day Surgery Clinic","startDate":"2019-09-20","conditions":["Ovarian Response"],"enrollment":160,"completionDate":"2023-01-31"},{"nctId":"NCT02703584","phase":"PHASE4","title":"Co Administration of GnRH Agonist and hCG for Final Oocyte Maturation","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2016-03","conditions":["Infertility"],"enrollment":276,"completionDate":"2018-09"},{"nctId":"NCT04854707","phase":"","title":"An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data","status":"COMPLETED","sponsor":"IVFarma LLC","startDate":"2020-01-12","conditions":["Reproductive Issues","Reproductive Disorder","Fertility Disorders","Fertility Issues","Gynecologic Disease","IVF"],"enrollment":5484,"completionDate":"2021-01-20"},{"nctId":"NCT00003653","phase":"PHASE3","title":"Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1999-01-05","conditions":["Prostate Cancer"],"enrollment":1386,"completionDate":"2013-01-10"},{"nctId":"NCT03946722","phase":"PHASE4","title":"Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer.","status":"UNKNOWN","sponsor":"University College, London","startDate":"2020-08-17","conditions":["Adenomyosis"],"enrollment":162,"completionDate":"2024-05-17"},{"nctId":"NCT01980680","phase":"PHASE4","title":"The Exogenous Progesterone Free Luteal Phase After GnRHa Trigger - a Pilot Study in Normo-responder IVF Patients","status":"COMPLETED","sponsor":"Peter Humaidan","startDate":"2014-12","conditions":["Infertility"],"enrollment":50,"completionDate":"2020-05"},{"nctId":"NCT00004054","phase":"PHASE3","title":"Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2000-01","conditions":["Prostate Cancer"],"enrollment":397,"completionDate":"2013-11"},{"nctId":"NCT02480127","phase":"NA","title":"Molecular Evaluation of Endometrium After Endometrial Injury","status":"COMPLETED","sponsor":"Royan Institute","startDate":"2014-09","conditions":["Endometrial Injury"],"enrollment":20,"completionDate":"2020-03"},{"nctId":"NCT02742675","phase":"PHASE2","title":"Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2015-09","conditions":["Prostate Cancer"],"enrollment":200,"completionDate":"2023-03"},{"nctId":"NCT00002633","phase":"PHASE3","title":"Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1995-02-08","conditions":["Prostate Cancer"],"enrollment":361,"completionDate":"2012-01-06"},{"nctId":"NCT00528866","phase":"PHASE2","title":"Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2008-04","conditions":["Prostate Cancer"],"enrollment":80,"completionDate":"2018-05-14"},{"nctId":"NCT02487823","phase":"PHASE1","title":"Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer","status":"TERMINATED","sponsor":"Institut Paoli-Calmettes","startDate":"2014-10","conditions":["Non Castrate Metastatic Prostate Cancer"],"enrollment":6,"completionDate":"2017-11"},{"nctId":"NCT01816789","phase":"PHASE4","title":"Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles","status":"TERMINATED","sponsor":"Andros Day Surgery Clinic","startDate":"2013-03","conditions":["In Vitro Fertilization","Ovarian Stimulation"],"enrollment":194,"completionDate":"2016-07"},{"nctId":"NCT01603420","phase":"PHASE2,PHASE3","title":"External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer","status":"TERMINATED","sponsor":"Proton Collaborative Group","startDate":"2012-07","conditions":["Prostate Cancer"],"enrollment":2,"completionDate":"2014-05"},{"nctId":"NCT00436319","phase":"PHASE4","title":"Duration of GnRH-analogue Downregulation and Pregnancy Rates","status":"TERMINATED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2006-05","conditions":["Infertility"],"enrollment":300,"completionDate":""},{"nctId":"NCT00749853","phase":"PHASE3","title":"Efficacy of Ovarian Stimulation Based on FSHR Genotype Status","status":"SUSPENDED","sponsor":"Medical University of Vienna","startDate":"2015-05","conditions":["Sterility"],"enrollment":165,"completionDate":"2015-06"},{"nctId":"NCT00175396","phase":"PHASE3","title":"Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2004-05","conditions":["Prostate Cancer"],"enrollment":400,"completionDate":"2014-06"},{"nctId":"NCT00823004","phase":"PHASE1,PHASE2","title":"Antagonist/Letrozole in Poor Responders","status":"COMPLETED","sponsor":"Yazd Research & Clinical Center for Infertility","startDate":"2008-06","conditions":["Ovarian Stimulation"],"enrollment":120,"completionDate":"2009-10"},{"nctId":"NCT00627406","phase":"PHASE4","title":"Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles","status":"COMPLETED","sponsor":"Regionshospitalet Viborg, Skive","startDate":"2009-01","conditions":["OHSS (Ovarian Hyperstimulation)"],"enrollment":384,"completionDate":"2011-12"},{"nctId":"NCT01888744","phase":"PHASE4","title":"Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2010-09","conditions":["Reproductive Endocrinology","Fertility","Optimal Stimulation Protocol"],"enrollment":120,"completionDate":"2013-06"},{"nctId":"NCT01819285","phase":"PHASE3","title":"Early Compared With Delayed Hormone Therapy in Treating Patients With Nonmetastatic Prostate Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1990-02","conditions":["Neoplasm, Prostate"],"enrollment":985,"completionDate":"2010-09"},{"nctId":"NCT01636505","phase":"PHASE3","title":"The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol","status":"UNKNOWN","sponsor":"European Hospital","startDate":"2012-09","conditions":["Embryo's Genetic and Chromosomal Quality"],"enrollment":200,"completionDate":"2013-09"},{"nctId":"NCT01213147","phase":"PHASE4","title":"Mild Stimulation Protocol Versus Microdose Gonadotropin-releasing Hormone Agonist Flare up Protocol in Poor Responders","status":"COMPLETED","sponsor":"Yazd Medical University","startDate":"2009-04","conditions":["Pregnancy"],"enrollment":159,"completionDate":"2010-05"},{"nctId":"NCT00823121","phase":"PHASE1,PHASE2","title":"Replacement of Fresh Embryo Transfers (ETs) by Frozen Embryo Transfers (FETs) Using Vitrification","status":"UNKNOWN","sponsor":"Yazd Research & Clinical Center for Infertility","startDate":"2008-08","conditions":["In Vitro Fertilization"],"enrollment":500,"completionDate":"2009-12"},{"nctId":"NCT00830492","phase":"PHASE4","title":"Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist","status":"COMPLETED","sponsor":"Yazd Research & Clinical Center for Infertility","startDate":"2008-01","conditions":["Ovarian Stimulation"],"enrollment":200,"completionDate":"2008-12"},{"nctId":"NCT00823602","phase":"PHASE3","title":"Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH","status":"UNKNOWN","sponsor":"Yazd Research & Clinical Center for Infertility","startDate":"2008-03","conditions":["Infertility"],"enrollment":2,"completionDate":"2009-01"},{"nctId":"NCT00461916","phase":"PHASE4","title":"Half-Dose Depot Triptorelin Versus Reduced-Dose Daily Buserelin","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2005-05","conditions":["Infertility"],"enrollment":182,"completionDate":"2006-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000170309","NDDF":"003708","UNII":"PXW8U3YXDV","CHEBI":"CHEBI:135907","INN_ID":"4045","RXNORM":"1825","UMLSCUI":"C0006456","chemblId":"CHEMBL2106198","ChEMBL_ID":"CHEMBL2110824","KEGG_DRUG":"D07259","DRUGBANK_ID":"DB06719","PUBCHEM_CID":"50225","SNOMEDCT_US":"327301004","IUPHAR_LIGAND_ID":"3860","SECONDARY_CAS_RN":"68630-75-1","MESH_DESCRIPTOR_UI":"D002064"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Sanofi K.K.","relationship":"Current Owner"}],"publicationCount":1472,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"L02AE01","allCodes":["L02AE01"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Apr 1","pmid":"41538921","title":"Reproductive efficiency of Bos indicus cows under different estradiol-free ovulation synchronization protocols.","journal":"Theriogenology"},{"date":"2026 Jan 5","pmid":"41489804","title":"Effect on insulin clearance of different pharmacological treatments in women with polycystic ovary syndrome: a hypothesis-generative study.","journal":"Journal of endocrinological investigation"},{"date":"2025 Dec","pmid":"41473569","title":"Optimal timing for triggering oocyte maturation during in vitro fertilization cycles varies between gonadotropin-releasing hormone agonist and human chorionic gonadotropin use.","journal":"F&S reports"},{"date":"2026 Mar 1","pmid":"41397337","title":"Association of buserelin acetate with estradiol benzoate in early resynchronization of Bos taurus beef heifers improved conception rates.","journal":"Theriogenology"},{"date":"2026 Jan","pmid":"41343948","title":"Estradiol esters are dispensable in progesterone-based TAI protocols for Bos taurus suckling beef cows.","journal":"Animal reproduction science"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Sanofi K.K.","companyId":"sanofi","modality":"Recombinant protein","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:10:30.354891+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}